In metastatic hormone-sensitive prostate cancer (mHSPC), adding the radioligand 177 Lu-PSMA-617 (Pluvicto) to androgen ...

Local radiation therapy appears beneficial for men with bone metastatic hormone-sensitive prostate cancer (mHSPC).

Bayer BAYRY announced that it has submitted a marketing authorization application (MAA) to the European Medicines Agency ...

A guideline panel indirectly studied cardiotoxicity among advanced prostate cancer treatments (mHSPC, mCRPC, CRPC).

Bayer is seeking EMA approval for darolutamide in metastatic hormone-sensitive prostate cancer, building on promising Phase ...

DelveInsight's 'Metastatic Castration-Sensitive Prostate Cancer Pipeline Insight 2024' report provides comprehensive global ...

Bayer seeks European approval for darolutamide in combo with ADT in patients with metastatic hormone-sensitive prostate cancer: Berlin Wednesday, October 16, 2024, 13:00 Hrs [IST] ...

Baseline circulating tumor cell count “may serve as a valuable, noninvasive biomarker” for patients with metastatic hormone-sensitive prostate cancer, according to researchers.

The sNDA is seeking approval of darolutamide, in combination with androgen deprivation therapy (ADT), in patients with metastatic hormone-sensitive prostate cancer (mHSPC). Darolutamide is an oral ...

In this feature we spoke to Michael J. Morris, MD, and Benjamin Garmezy, MD, on the future of radioligand therapy in patients ...

Reuters, the news and media division of Thomson Reuters, is the world’s largest multimedia news provider, reaching billions of people worldwide every day. Reuters provides business, financial ...

A shadowy network of ships has registered in Gabon, highlighting how Vladimir V. Putin is building an economy beyond the reach of Western sanctions. By Rebecca R. Ruiz and Jacob Judah President ...